Novo Nordisk A/S – Share repurchase programme
August 31 2020 - 9:03AM
Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 31 August 2020 – On 6 August
2020, Novo Nordisk initiated a share repurchase programme in
accordance with Article 5 of Regulation No 596/2014 of the European
Parliament and Council of 16 April 2014 (MAR) and the Commission
Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe
Harbour Rules"). This programme is part of the overall share
repurchase programme of up to DKK 17 billion to be executed during
a 12-month period beginning 5 February 2020.
Under the programme initiated 6 August 2020, Novo Nordisk will
repurchase B shares for an amount up to DKK 2.8 billion in the
period from 6 August 2020 to 28 October 2020.
Since the announcement as of 24 August 2020, the following
transactions have been made:
|
Number ofB shares |
Averagepurchase price |
Transactionvalue, DKK |
Accumulated, last announcement |
1,344,000 |
|
557,723,775 |
24 August
2020 |
110,000 |
421.08 |
46,319,095 |
25 August
2020 |
110,000 |
418.69 |
46,056,234 |
26 August
2020 |
110,000 |
419.60 |
46,155,817 |
27 August
2020 |
110,000 |
420.02 |
46,201,740 |
28 August
2020 |
110,000 |
414.88 |
45,636,660 |
Accumulated under the programme |
1,894,000 |
|
788,093,321 |
The details for each transaction made under the share repurchase
programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of
21,941,903 B shares of DKK 0.20 as treasury shares, corresponding
to 0.9% of the share capital. The total amount of A and B shares in
the company is 2,350,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to
DKK 17 billion during a 12-month period beginning 5 February 2020.
As of 28 August 2020, Novo Nordisk has since 5 February 2020
repurchased a total of 21,953,179 B shares at an average share
price of DKK 425.40 per B share equal to a transaction value of DKK
9,338,881,053.
Novo Nordisk is a leading global healthcare company, founded in
1923 and headquartered in Denmark. Our purpose is to drive change
to defeat diabetes and other serious chronic diseases such as
obesity and rare blood and endocrine disorders. We do so by
pioneering scientific breakthroughs, expanding access to our
medicines and working to prevent and ultimately cure disease. Novo
Nordisk employs about 43,100 people in 80 countries and markets its
products in around 170 countries. Novo Nordisk's B shares are
listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the
New York Stock Exchange (NVO). For more information, visit
novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.
Further information
Media: |
|
|
Anne Margrethe
Hauge |
+45 4442 3450 |
amhg@novonordisk.com |
Ken Inchausti
(US) |
+1 609 240
9429 |
kiau@novonordisk.com |
|
|
|
Investors: |
|
|
Daniel Muusmann
Bohsen |
+45 3075 2175 |
dabo@novonordisk.com |
Valdemar Borum
Svarrer |
+45 3079 0301 |
jvls@novonordisk.com |
Ann Søndermølle
Rendbæk |
+45 3075 2253 |
arnd@novonordisk.com |
Mark Joseph
Root |
+45 3079 4211 |
mjhr@novonordisk.com |
Kristoffer Due
Berg (US) |
+1 609 235
2989 |
krdb@novonordisk.com |
Company announcement no. 52 / 2020
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From Sep 2023 to Sep 2024